Impact News +++ ROUNDUP: PNE bestätigt möglichen Komplettverkauf - Preisvorstellung unter Kurs (DPA-AFX) +++ PNE Aktie -3,28%

OCUGEN Aktie

>OCUGEN Aktienkurs

1.13 EUR +2.4% (TradegateBSX)

Ask: 1.148 EUR / 5000 Stück

Bid: 1.114 EUR / 5000 Stück

Tagesumsatz: 31585 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OCUGEN Aktie über LYNX handeln

Intraday

1 Jahr

>OCUGEN Performance

1 Woche: +4,4%

1 Monat: -12,7%

3 Monate: -11,4%

6 Monate: -5,5%

1 Jahr: +31,4%

laufendes Jahr: -9,8%

>OCUGEN Aktie

Profil:

Ocugen Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that address serious unmet medical needs. The company’s core emphasis is on ophthal..
>Volltext..

Insiderhandel:

>OCUGEN Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>OCUGEN Peer Group

Gesundheit, Augenmedizin/ Sehhilfen, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Covid 19- Behandlung/ post Covid/ long Covid

>OCUGEN Chart & Kurs - NASDAQ

>OCUGEN News

07.08.26 - 20:30	Ocugen′s Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls (Zacks)
	OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028....

06.08.26 - 13:06	Ocugen Provides Business Update with Second Quarter 2026 Financial Results (GlobeNewswire EN)
	Conference Call and Webcast Today at 8:30 a.m. ET...

05.08.26 - 18:06	Ocugen Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.26 - 13:06	Ocugen to Participate in Upcoming August Investor Conferences (GlobeNewswire EN)
	MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026....

29.07.26 - 13:06

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire EN)

MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Ocugen's investigational product OCU410 for the treatment of geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD)....

28.07.26 - 22:06	Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire EN)
	MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 6, 2026....

13.07.26 - 13:27	Ocugen signs OCU400 licensing term sheet (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.07.26 - 13:06

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa (GlobeNewswire EN)

MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region....

10.07.26 - 16:54	Ocugen treibt Gentherapie-Pipeline für Augenerkrankungen voran (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.26 - 13:03	Ocugen to Participate in Upcoming July Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026....

18.06.26 - 03:01	Insiderhandel: Chief Financial Officer kauft Aktien von Ocugen im Wert von 25830 USD (Insiderkauf)
	Johnson-Greene, Treerita Essalima - Vorstand - Tag der Transaktion: 2026-06-15...

04.06.26 - 19:00	Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report? (Zacks)
	Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

03.06.26 - 19:45	Ocugen′s Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care (Zacks)
	OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027....

03.06.26 - 19:00	OCGN′s Catalyst Calendar for Trial Data and Filings Through 2028 (Zacks)
	Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach....

03.06.26 - 19:00	Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? (Zacks)
	Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase....

02.06.26 - 13:06	Ocugen to Participate in Upcoming June Investor and Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026....

26.05.26 - 10:27	Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.05.26 - 10:00	Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.26 - 22:33	Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes (GlobeNewswire EN)
	Includes Full Exercise of $15.0 million Over-Allotment Option Includes Full Exercise of $15.0 million Over-Allotment Option...

13.05.26 - 13:06	Ocugen to Participate in Upcoming May Scientific and Investor Conferences (GlobeNewswire EN)
	MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werturteile sind nie Wahrheiten, sondern Wünsche, die meist erst wahr gemacht werden sollen. - Ludwig Marcuse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram